ESMO 2023 Lung Cancer - Chapter 2 Highlights – PAPILLON, MARIPOSA, MARIPOSA-2, LIBRETTO-431

Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATICПодробнее

Highlights in lung cancer at ESMO 2023: PAPILLON and MARIPOSAПодробнее

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

MARIPOSA/MARIPOSA-2 ESMO 2024 - Importance of Amivantamab in mNSCLC Insights on Resistance PatternsПодробнее

ESMO 2023 highlights: advances in EGFR+ lung cancer second-line therapyПодробнее

Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 studyПодробнее

New Standard of care Treatment for EGFR Exon 20 Non-small cell Lung Cancer | Dr. Alexander SpiraПодробнее

Highlights on Tisotumab Vedotin 2L or 3L Recurrent or Metastatic Cervical Cancer: innovaTV 301Подробнее

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinibПодробнее

Post-progression analysis of MARIPOSA-2: amivantamab + chemo in EGFR+ NSCLCПодробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее

Lung ESMO 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Joshua ReussПодробнее

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 studyПодробнее

TracerX NSCLC Study from ESMO 2023 - Dr. Richard ChenПодробнее